Edition:
United States

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

36.31USD
16 Nov 2018
Change (% chg)

$-0.34 (-0.93%)
Prev Close
$36.65
Open
$36.44
Day's High
$37.55
Day's Low
$34.97
Volume
391,776
Avg. Vol
271,858
52-wk High
$68.05
52-wk Low
$31.50

Latest Key Developments (Source: Significant Developments)

GBT Q3 Loss Per Share $0.83
Tuesday, 6 Nov 2018 04:05pm EST 

Nov 6 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND PROVIDES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.83.Q3 EARNINGS PER SHARE VIEW $-0.86 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $482.1 MILLION AT SEPTEMBER 30, 2018.  Full Article

GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis
Thursday, 23 Aug 2018 08:00am EDT 

Aug 23 (Reuters) - Global Blood Therapeutics Inc ::GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS.GLOBAL BLOOD THERAPEUTICS INC - ENTERED INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD.GLOBAL BLOOD THERAPEUTICS INC - AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF INCLACUMAB.GLOBAL BLOOD THERAPEUTICS INC - GBT WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION OF INCLACUMAB WORLDWIDE.GLOBAL BLOOD THERAPEUTICS INC - ROCHE WILL RECEIVE AN UPFRONT PAYMENT OF $2.0 MILLION FROM GBT.GLOBAL BLOOD THERAPEUTICS INC - ROCHE IS ELIGIBLE TO RECEIVE UP TO ABOUT $125 MILLION IN MILESTONE PAYMENTS FOR SICKLE CELL DISEASE INDICATION.GLOBAL BLOOD THERAPEUTICS INC - GBT HAS ALREADY BEGUN PROCESS OF TECHNOLOGY TRANSFER FROM ROCHE TO A CONTRACT MANUFACTURING ORGANIZATION.GLOBAL BLOOD THERAPEUTICS - EXPECTS SUBMITTING IND APPLICATION TO U.S. FDA FOR INCLACUMAB IN 2021.GLOBAL BLOOD THERAPEUTICS - ADDITIONALLY, ROCHE IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET REVENUES FOR INCLACUMAB.  Full Article

Global Blood Therapeutics ‍priced underwritten public offering of 4.0 mln shares of its common stock
Thursday, 8 Mar 2018 10:00pm EST 

March 8 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF 4,000,000 SHARES OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC-‍PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 4.0 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $54.00 PER SHARE​.  Full Article

Global Blood Therapeutics Announces Proposed Public Offering
Thursday, 8 Mar 2018 04:01pm EST 

March 8 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 3.50 MILLION COMMON SHARES.  Full Article

Global Blood Therapeutics Q4 Loss Per Share $0.94
Tuesday, 27 Feb 2018 04:07pm EST 

Feb 27 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.94.  Full Article

GBT Receives Fda Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease
Tuesday, 9 Jan 2018 08:00am EST 

Jan 9 (Reuters) - Global Blood Therapeutics Inc ::GBT RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE (SCD).  Full Article

Global Blood Therapeutics Prices A $100.0 Mln Common Stock Public Offering
Friday, 15 Dec 2017 09:03am EST 

Dec 15 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS PRICES A $100.0 MILLION COMMON STOCK PUBLIC OFFERING.  Full Article

Global Blood Therapeutics To Sell $100 Mln In Public Offering Of Shares
Thursday, 14 Dec 2017 04:00pm EST 

Dec 14 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - ANNOUNCED AN AGREEMENT TO SELL $100.0 MILLION IN SHARES OF ITS COMMON STOCK.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR FOR TREATMENT OF SICKLE CELL DISEASE.  Full Article

Global Blood Therapeutics posts Q3 loss per share $0.66
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Global Blood Therapeutics Inc :Global Blood Therapeutics reports recent business progress and provides third quarter 2017 financial results.Q3 loss per share $0.66.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Global Blood Therapeutics - continue to expect cash,cash equivalents,marketable securities to be enough to take co to top-line data in hope study​.Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016​.  Full Article

Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440
Tuesday, 24 Oct 2017 08:00am EDT 

Oct 24 (Reuters) - Global Blood Therapeutics Inc ::Global Blood Therapeutics announces approval of first-in-class “voxelotor” as nonproprietary name for gbt440.Global Blood Therapeutics Inc - ‍world Health Organization has approved "voxelotor" as international nonproprietary name for gbt440​.  Full Article

BRIEF-GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis

* GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS